An ongoing phase 2 clinical trial is evaluating the efficacy and tolerability of fixed-duration zanubrutinib plus venetoclax for relapsed / refractory CLL.
Serious infections are a key issue in CLL. Real-world data show they occur significantly less with zanubrutinib than with venetoclax and obinutuzumab.
Zanubrutinib, a newer BTK inhibitor, showed 60-month progression-free survival (PFS) in frontline high-risk CLL / SLL patients with del(17p)
Combining zanubrutinib with venetoclax results in nearly a 100% response rate in frontline CLL / SLL patients.
Patients with CLL / SLL who were treated with zanubrutinib continue to experience deep sustained responses six years out with no new safety issues.
With five years of follow-up, zanubrutinib continues to provide greater progression-free survival in treatment-naïve patients with CLL / SLL.
Patients with CLL who were able to rapidly clear measurable residual disease (MRD) needed less treatment and experienced longer remissions.
The combination of sonrotoclax and zanubrutinib was well-tolerated and produced high rates of undetectable disease in patients with treatment-naïve CLL.
Combining the new BCL2 inhibitor sonrotoclax with the BTK inhibitor zanubrutinib produced an overall response rate of 97% in relapsed CLL / SLL.
